Janus Henderson Group PLC Has $617.73 Million Stock Holdings in Vaxcyte, Inc. $PCVX

Janus Henderson Group PLC lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 2.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 13,387,188 shares of the company’s stock after purchasing an additional 282,985 shares during the quarter. Janus Henderson Group PLC owned about 10.23% of Vaxcyte worth $617,731,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. EcoR1 Capital LLC acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $20,763,000. Elmind Capital LP acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $13,450,000. Boothbay Fund Management LLC grew its position in shares of Vaxcyte by 286.7% in the 4th quarter. Boothbay Fund Management LLC now owns 497,740 shares of the company’s stock valued at $22,966,000 after purchasing an additional 369,009 shares during the period. Logos Global Management LP grew its position in shares of Vaxcyte by 4.0% in the 4th quarter. Logos Global Management LP now owns 650,000 shares of the company’s stock valued at $29,991,000 after purchasing an additional 25,000 shares during the period. Finally, Caligan Partners LP acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $78,660,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Jim Wassil sold 2,250 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares in the company, valued at $7,848,622.88. This represents a 1.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the sale, the chief accounting officer owned 28,975 shares in the company, valued at approximately $1,738,500. This represents a 9.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 7,500 shares of company stock worth $419,288. Company insiders own 3.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PCVX. BTIG Research upped their price target on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Stock Up 2.8%

NASDAQ:PCVX opened at $50.67 on Thursday. Vaxcyte, Inc. has a twelve month low of $29.08 and a twelve month high of $65.00. The business has a 50 day moving average price of $53.74 and a two-hundred day moving average price of $52.69. The company has a market cap of $7.32 billion, a P/E ratio of -7.36 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the business earned ($1.04) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.